Dimensional Fund Advisors LP Has $12 Million Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Dimensional Fund Advisors LP lessened its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 10.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 707,404 shares of the biotechnology company's stock after selling 85,196 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.61% of Arcturus Therapeutics worth $12,004,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in ARCT. Franklin Resources Inc. grew its position in shares of Arcturus Therapeutics by 54.6% in the third quarter. Franklin Resources Inc. now owns 103,936 shares of the biotechnology company's stock valued at $2,412,000 after purchasing an additional 36,714 shares in the last quarter. Nordea Investment Management AB increased its holdings in Arcturus Therapeutics by 3.7% in the 4th quarter. Nordea Investment Management AB now owns 65,778 shares of the biotechnology company's stock worth $1,097,000 after acquiring an additional 2,335 shares in the last quarter. Hennion & Walsh Asset Management Inc. grew its holdings in shares of Arcturus Therapeutics by 139.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 82,057 shares of the biotechnology company's stock worth $1,393,000 after purchasing an additional 47,824 shares during the period. SG Americas Securities LLC boosted its holdings in Arcturus Therapeutics by 45.0% in the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company's stock valued at $203,000 after purchasing an additional 3,705 shares in the last quarter. Finally, Spire Wealth Management grew its holdings in shares of Arcturus Therapeutics by 393.3% in the 4th quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company's stock worth $229,000 after acquiring an additional 10,746 shares during the period. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the company. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a "buy" rating in a report on Monday, March 10th. Canaccord Genuity Group reduced their target price on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating on the stock in a research report on Friday, March 7th. Finally, HC Wainwright reiterated a "buy" rating and set a $60.00 price target on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics presently has a consensus rating of "Buy" and a consensus price target of $58.80.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT traded up $0.27 during mid-day trading on Tuesday, reaching $11.86. The company's stock had a trading volume of 783,627 shares, compared to its average volume of 452,248. Arcturus Therapeutics Holdings Inc. has a 52 week low of $8.04 and a 52 week high of $45.00. The firm has a market capitalization of $321.66 million, a PE ratio of -5.34 and a beta of 2.36. The stock has a fifty day moving average of $11.78 and a two-hundred day moving average of $15.38.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. Analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.